Elasmogen Ltd

Elasmogen Ltd is dedicated to improving the outcomes and quality of life for individuals combating autoimmune diseases, both now and in the future. As a therapeutic biologics company, Elasmogen specializes in developing dual-targeting products designed to address difficult-to-treat autoimmune conditions.

Elasmogen's lead product, ELN28, represents a first-in-class approach, meticulously designed to target the specific site of inflammation. At this location, it effectively neutralizes soluble TNFa while safely and specifically delivering a Janus kinase inhibitor. This innovative method seeks to break the efficacy ceiling associated with current therapies.

Elasmogen Ltd is committed to progressing ELN28 to clinical trials, with the goal of providing rapid control and long-term remission for autoimmune patients who currently experience poorly controlled disease. For more information about Elasmogen and its groundbreaking work, please visit http://www.elasmogen.com. We invite the management team at Elasmogen to create a customized and exclusive company showcase and product listing on our platform to further highlight their innovative solutions.